Laura Alonso is an Endocrinology/Metabolic physician affiliated with Weill Cornell Medicine. OpenAlex indexes 104 publications with 4,738 citations (h-index 38); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
211 E 80th St Fl 2
New York, NY 100750531
Telephone
646-962-8690Provider last certified this registry record 15 Jan 2020.
Clinical trials
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
3 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- VERTEX PHARMACEUTICALS INCORPORATEDProgram year20258 payments
- Lilly USA, LLCProgram year20251 payment
- Boehringer Ingelheim Pharmaceuticals, Inc.Program year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Metabolism & gastrointestinal
84.8%GLP-1 receptor agonist31.2%Mounjaro50%Ozempic50%Part D≥15 patientsSGLT2 inhibitor22.3%Jardiance100%Part D≥17 patients+ 3 more classes in this area
Cardiovascular
10.4%ACE inhibitor5.6%Lisinopril100%Part D<11 patientsAngiotensin receptor blocker (ARB)4.8%Losartan Potassium100%Part D<11 patientsHormonal (systemic)
4.8%l-Thyroxine4.8%Levothyroxine Sodium100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
5 NIH research awards on record, funded 2019–2026 per NIH RePORTER. The latest:
- Benefits and harms of activating ATF6 in beta cells
Weill Medical Coll of Cornell Univ
FY2026$455,653R01DK135304 - Research Training in Endocrinology and Metabolism
Weill Medical Coll of Cornell Univ
FY2026$143,056T32DK131957
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Similar KOLs
Other experts from the same institution or the same specialty.
Jedd Wolchok, MD
Weill Cornell Medicine
Richard Devereux, MD
Weill Cornell Medicine
Ronald Crystal, MD
Weill Cornell Medicine
Robert Harrington, MD
Weill Cornell Medicine
Yousef Saleh Khader
Jordan University of Science and Technology
Jens Juul Holst
University of Copenhagen
Victor Montori, MD
Mayo Clinic
Christos Mantzoros, MD
Harvard Medical School
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”